Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

Z-003

Supelco

Zopiclone solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H17ClN6O3
CAS Number:
43200-80-2
Molecular Weight:
388.81
EC Number:
200-835-2
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

C[NH+]1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4

InChI

1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/p+1

InChI key

GBBSUAFBMRNDJC-UHFFFAOYSA-O

Related Categories

General description

A certified solution standard suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, pharmaceutical research, or urine drug testing.  Zopiclone is a non-benzodiazepine hypnotic sold under the trade names Imovane® and ZImovane® and is prescribed for the treatment of insomnia.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Imovane is a registered trademark of Sanofi-Aventis
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

PDSCL

Deleterious substance

FSL

Group 4: Flammable liquids
Type 1 petroleums
Hazardous rank II
Water insoluble liquid

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

Z-003-CC:
Z-003-1ML:4548173920467

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Judith Peacey et al.
The Journal of nervous and mental disease, 200(1), 83-87 (2012-01-03)
Adult patients (N = 100) being treated for acute psychiatric illness were interviewed about their sleep problems and attitudes toward available treatments. Most (74%) were using at least one prescribed psychotropic drug with hypnotic or sedative effects. Participants prescribed three
[Determination of zopiclone in serum by gas chromatographic method].
Zi-ru Cheng et al.
Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 30(4), 314-315 (2012-07-19)
Coma after single dose of zopiclone.
Annelie K Hintzen et al.
The American journal on addictions, 21(3), 291-291 (2012-04-13)
To breathe, perchance not to wake?
David M Rapoport
Journal of applied physiology (Bethesda, Md. : 1985), 112(2), 247-248 (2011-10-29)
Nico J Diederich et al.
Journal of the neurological sciences, 314(1-2), 12-19 (2011-11-29)
Sleep symptoms in Parkinson's disease (PD) are frequent and have multifactorial and multilayered causes. Primary involvement of sleep/wake regulating centers in the brainstem, sleep problems caused by the nocturnal manifestation of motor and dysautonomic signs and medication-induced sleep problems are
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service